EUVIMEDEUVIMED entdecken
CrossrefInfokarte

The Treatment Strategies for Intermediate‐Advanced Hepatocellular Carcinoma Based on Albumin–Bilirubin Grade: A Multicenter Retrospective Cohort Study

Kang Liang, Jianwei Liu, Xiaorong Pan, Yuxuan Lin, Kongying Lin, Hui Xue, Jing Li, Huichuan Sun, Kui Wang

Cancer Medicine · 2026-11 · 15 (11)

DOI: 10.1002/cam4.72415 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Background To evaluate whether the albumin–bilirubin (ALBI) grade modifies the association of combined locoregional plus systemic therapy versus systemic therapy alone with outcomes in unresectable hepatocellular carcinoma (HCC). Methods This multicente retrospective study enrolled 525 patients, stratified by the established ALBI grade cut‐off into ALBI‐low (Grade 1, ALBI score ≤ −2.60, n = 257) and ALBI‐high (Grade 2/3, n = 268). Propensity score matching (PSM) was performed in the whole cohort and within each ALBI stratum; survival, tumor response, and safety were compared in matched cohorts, with effect modification tested by a treatment × ALBI interaction term. Results After PSM, combination therapy was associated with better overall survival (OS) (hazard ratio [HR] 0.51, 95% confidence interval [CI] 0.34–0.76; p = 0.001) and progression‐free survival (PFS) (HR 0.73, 95% CI 0.56–0.96; p = 0.024). The association was observed in ALBI‐low patients (OS: HR 0.32, 95% CI 0.18–0.56, p < 0.001; PFS: HR 0.59, 95% CI 0.41–0.85, p = 0.004), who also had higher objective response rates by modified Response Evaluation Criteria in Solid Tumors (mRECIST; 70.9% vs. 38.8%, p < 0.001) and RECIST 1.1 (55.3% vs. 30.1%, p < 0.001). No significant association was seen in ALBI‐high patients (OS: HR 0.83, 95% CI 0.47–1.45, p = 0.504; PFS: HR 1.06, 95% CI 0.71–1.58, p = 0.792), and the treatment × ALBI interaction was significant for OS ( p = 0.019) and PFS ( p = 0.035). Overall and Grade 3–4 adverse reactions were comparable, but elevated bilirubin (33.0% vs. 17.0%, p = 0.012) and transaminases (35.1% vs. 20.2%, p = 0.022) were more frequent with combination therapy in the ALBI‐high cohort. Conclusion In this multicenter real‐world cohort, combination therapy was associated with better outcomes in patients of ALBI Grade 1 but not Grade 2/3, in whom hepatic toxicity was more frequent, and the exploratory treatment × ALBI interaction was significant. ALBI grade may help identify patients more likely to benefit from combined locoregional and systemic therapy, although prospective validation is required.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →